Nicholas Piramal in tie-up for cancer, diabetes research

11 Jun 2007

1

Mumbai: Nicholas Piramal India Ltd has initiated two basic research programmes to screen patient samples in the diabetes and cancer segments in order to develop biomarkers that could eventually lead to a targeted new drug development.

The company has recently forged a cancer-related alliance with Chennai''s Apollo Hospitals Group for the molecular profiling of tumors.

NPIL will do a "blind" study of the tumour samples provided by the hospital and compare the data with the hospital''s patient response to conventional therapy.

Biomarkers could be an external substance or a feature in the human body that helps indicate a pattern in the patient''s response to treatment.

A tool used for target identification, the biomarker technology is getting more refined over the years and it improves the chance of discovering a drug, observes a senior researcher with a clinical research organisation.

The company is finalisng a similar study with the diabetology group of Chennai''s Sri Ramachandra Medical College and Research Institute that would help evaluate specific markers for diabetes.

 

Business History Videos

History of hovercraft Part 3...

Today I shall talk a bit more about the military plans for ...

By Kiron Kasbekar | Presenter: Kiron Kasbekar

History of hovercraft Part 2...

In this episode of our history of hovercraft, we shall exam...

By Kiron Kasbekar | Presenter: Kiron Kasbekar

History of Hovercraft Part 1...

If you’ve been a James Bond movie fan, you may recall seein...

By Kiron Kasbekar | Presenter: Kiron Kasbekar

History of Trams in India | ...

The video I am presenting to you is based on a script writt...

By Aniket Gupta | Presenter: Sheetal Gaikwad

view more